Multiple sclerosis (MS) is widely described as an autoimmune disease, but the scientific picture is more nuanced than that label suggests. There is strong evidence that the immune system drives the damage in MS, yet researchers have not been able to confirm it meets every classical criterion for autoimmunity. In practice, MS is most accurately called an immune-mediated disease, one where the body’s own defenses attack the brain and spinal cord, even if the exact trigger remains unidentified.
Why the “Autoimmune” Label Is Complicated
For a disease to qualify as a classical autoimmune condition, scientists generally need to identify a specific self-protein (called an autoantigen) that the immune system mistakenly targets, and then show that attacking this protein is sufficient to cause the disease. In MS, several candidate proteins exist, most notably myelin basic protein, a major structural component of the protective coating around nerve fibers. Immune cells reactive against myelin basic protein have been found in people with MS, and injecting these cells into animals produces a similar demyelinating disease. But no single autoantigen has been definitively proven to be the universal trigger in all patients.
A review published in the Annals of Neurology put it plainly: from most references in the literature, MS is “boldly stated as an autoimmune disorder,” but the evidence for that statement is “weak and circumstantial.” What is not in dispute is that the immune system is central to the disease. The distinction matters mainly to researchers trying to find the root cause, not to patients seeking treatment, since therapies for MS already target the immune system directly.
What Happens Inside the Nervous System
MS damages the central nervous system through a process called demyelination. Myelin is the insulating sheath wrapped around nerve fibers, and it allows electrical signals to travel quickly and efficiently. When immune cells destroy myelin, nerve signals slow down or get blocked entirely, producing symptoms like numbness, vision problems, difficulty walking, and fatigue.
The damage doesn’t stop at myelin. Detailed studies of brain and spinal cord tissue from people with MS show that the nerve fibers themselves can be severely injured within active lesions. Myelin can regenerate to some degree, a process called remyelination. But once nerve fibers are lost, that damage is largely permanent, which is why early treatment matters so much.
Interestingly, not everyone’s lesions look the same under a microscope. Active MS lesions can be sorted into one of four distinct subtypes based on the type of immune activity present, and each person tends to show only a single pattern. This suggests that while all MS involves immune-driven damage, the specific mechanism may vary from patient to patient.
How Immune Cells Reach the Brain
The brain is normally protected by the blood-brain barrier, a tightly sealed layer of cells lining blood vessels that prevents most immune cells and large molecules from crossing into brain tissue. In MS, this barrier breaks down. Inflammatory signaling molecules loosen the junctions between barrier cells, making them leaky. They also cause the barrier’s surface to become stickier, which helps immune cells latch on and push their way through.
This disruption of the blood-brain barrier is one of the earliest abnormalities seen in MS and can be detected on MRI scans as areas of contrast enhancement. Once inside the brain, immune cells encounter myelin and nerve tissue, triggering inflammation and damage.
The Roles of T Cells and B Cells
Two major branches of the immune system contribute to MS. T cells, particularly certain subtypes of helper T cells and killer T cells, are found in high numbers within active lesions and produce inflammatory molecules that directly damage myelin. In brain tissue from people who have died with MS, higher T cell counts in white matter lesions consistently correspond with more active demyelination.
B cells were long considered secondary players, but their role has turned out to be critical. B cells can reactivate T cells inside the brain and spinal cord, amplifying inflammation. They also form cluster-like structures in the brain’s membranes that resemble the immune hubs normally found in lymph nodes, creating a persistent source of immune activation right next to vulnerable tissue. The dramatic success of therapies that deplete B cells has been one of the strongest pieces of evidence that these cells are central to the disease process.
Genetics and Environmental Triggers
MS is not caused by a single gene, but genetics clearly influence risk. The strongest known genetic factor is a variant of a gene involved in how the immune system identifies threats, called HLA-DRB1*15:01. Carrying this variant significantly raises MS risk, especially when combined with certain environmental exposures.
The most well-established environmental trigger is infection with Epstein-Barr virus (EBV), the common virus that causes mononucleosis. Higher levels of antibodies against a specific EBV protein have been linked to increased MS risk, and the combination of this viral exposure with the HLA-DRB1*15:01 gene variant raises risk further. Smoking is another confirmed risk factor and interacts with the same genetic variant. Even adolescent obesity and low sun exposure during youth have been associated with higher rates of MS. A large Swedish study found that alcohol abstinence, somewhat unexpectedly, also interacted with both the high-risk gene and smoking to increase susceptibility.
Globally, about 1.89 million people live with MS, with over 62,000 new cases diagnosed in 2021. The disease is far more common at higher latitudes: Sweden has the highest prevalence at 219 cases per 100,000 people, followed by Canada at 182 and Norway at 176. This geographic pattern is one reason researchers suspect that vitamin D levels, which depend partly on sunlight exposure, play a role.
How MS Is Diagnosed
Diagnosis relies on showing that damage has occurred in multiple areas of the central nervous system, a principle called dissemination in space. The most recent update to the diagnostic criteria, revised in 2024, now recognizes five regions that count toward this requirement: the optic nerve, the brain’s cortex, the area around the brain’s fluid-filled cavities, the brainstem and cerebellum, and the spinal cord. Damage in at least two of these five regions is needed.
Previously, doctors also needed to show that damage occurred at more than one point in time (dissemination in time). The updated criteria relaxed this requirement. If a person has lesions in at least two regions and also has specific immune markers in their spinal fluid, that can now be enough for a diagnosis even without evidence of attacks at different times. This change allows earlier diagnosis for some patients, which means earlier access to treatment.
Why Treatments Target the Immune System
Regardless of whether MS is labeled “autoimmune” or “immune-mediated,” the treatment strategy is the same: calm or redirect the immune response before it can damage more nerve tissue. Disease-modifying therapies for MS work through several distinct strategies, and their success is itself strong evidence that the immune system is the primary driver of the disease.
Some therapies work by trapping activated immune cells in the lymph nodes so they never reach the bloodstream. Others block immune cells from crossing the blood-brain barrier, essentially reinforcing the barrier that MS weakens. A third approach depletes specific immune cell populations entirely, particularly T cells and B cells, allowing the immune system to slowly rebuild with less aggressive cells. Still others shift the immune system’s overall profile from an inflammatory state toward a calmer, more regulatory one.
These treatments can significantly reduce the frequency and severity of relapses, slow the accumulation of disability, and in some cases produce long periods with no detectable disease activity on MRI. They do not cure MS, and they carry their own risks because suppressing the immune system can make infections more likely. But they represent concrete evidence that controlling immune activity controls the disease, which is ultimately more important for patients than whether the terminology says “autoimmune” or “immune-mediated.”